Mylan N.V. (MYL) Gain Is Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Pain


Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) shares are diving nearly 15% in Wednesday’s trading session, following the news that competitor Mylan N.V. (NASDAQ:MYL) has won FDA approval for generic version of Teva’s Copaxone. Mylan notes it plans to “begin shipping imminently.”

Oppenheimer analyst Derek Archila commented, “Our 4Q17 Copaxone forecast of ~$745M (vs. Street’s ~$876M) already assumed a generic 40mg launch, and management has in the past quantified a full-quarter impact in 2017 from “one or more” 40mg generics as a ~20-25c headwind to its 2017 EPS guidance of $4.30- $4.50 (our 2017 EPS estimate is $4.17 vs. consensus of $4.31). Recall a generic was not factored into guidance. We believe a ~5% move to the downside is an appropriate move for the stock based on the news. Our 2018-2022 estimates already assume meaningful erosion to the Copaxone franchise (our 2018 estimate is ~$2.5B, -30% y/y) from several generic competitors.”

“Consensus estimates generally seem to take generic competition into account, albeit in varying degrees of magnitude (2018 estimates range from ~$1.7B-$3.7B). We believe MYL will likely be aggressive in trying to secure meaningful share of both the 20mg and 40mg presentations and noted a patient support service in order to capture new patient starts and switches,” the analyst added.

Archila rates TEVA a Market Perfom, without suggesting a price target. (To watch Archila’s track record, click here)

Overall, 3 sell-side analysts have rated the stock with a Sell rating, 12 analysts have assigned a Hold rating and 2 have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $18.50 which is -1.7% under where the stock closed yesterday.

Teva is a global pharmaceutical company, which provides patient-centric healthcare solutions. It operates through two segments: Generic Medicines and Specialty Medicines. The Generic Medicines segment includes chemical and therapeutic equivalents of originator medicines in a variety of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. The Specialty Medicine segment engages in the provision of core therapeutic areas of central nervous system medicines.

 

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts